Long-term cabergoline use does not predict degree of prolactinoma fibrosis nor significantly impact surgical outcomes. [PDF]
Mamelak AN +9 more
europepmc +1 more source
Cystic versus non-cystic prolactinoma: clinical, hormonal, radiological, and remission outcomes in Basrah. [PDF]
Reman KA +4 more
europepmc +1 more source
Multiple endocrine neoplasia with an atypical clinical course and a MEN1 gene variant of uncertain pathogenicity: A case report. [PDF]
Sato S, Arahata M, Kumano Y, Kawai K.
europepmc +1 more source
Cabergoline-Resistant Recurrent Macroprolactinoma During Pregnancy: A Case Report and Review of the Literature. [PDF]
Alajpur S +3 more
europepmc +1 more source
Management outcomes of prolactinoma: a retrospective study from Southern Iraq. [PDF]
Alobaidy HF +5 more
europepmc +1 more source
Cabergoline monotherapy in GH- and PRL-cosecreting pituitary adenomas. [PDF]
McNeil JM +3 more
europepmc +1 more source
The Differences Between Dopamine Agonist-Resistant and -Non-Resistant Prolactinomas: Are There Any Predictors of a Good Response? [PDF]
Komisarz-Calik M +9 more
europepmc +1 more source
Somatostatin 5 receptor expression in prolactinomas: Is there a role for Pasireotide in the management of prolactinomas? [PDF]
Agrawal N +11 more
europepmc +1 more source

